IDH2 and astrocytoma (excluding glioblastoma): However, these factors have prognostic value rather than predictive power that qualify for effective treatment (voradisenib has limited efficacy in patients with astrocytoma or oligoastrocytoma with an IDH mutation) [1,2,3,4,5,6,7].